News

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth’s founder and CEO, discusses how patients are affected by these supply chain bottlenecks, along with ways to mitigate these complications.

New production line represents Rentschler Biopharma SE’s biggest investment in its 150-year history.

In an interview with Pharma Commerce editor Nicholas Saraceno, Peter Ax, UpScriptHealth's founder and CEO, offers his thoughts surrounding the lack of supply.

Why these programs require a hybrid approach that combines technology and human connection.

The merger combines the companies under the MedPharma name, creating a topical and transepithelial CDMO in the process.

An economic evaluation study assesses these costs by therapeutic class, while identifying trends in pharma R&D intensity over time.

Expansion of these offerings will occur at the company’s 60,000 square-foot Lincolnshire Center of Excellence

Double-digit, year-on-year growth is now on a six-month streak.

An observational, retrospective cohort study undergoes this investigation in individuals 24 years of age or older.

The investment is expected to help enhance the company temperature-controlled services in the Netherlands, France, Italy, and Hungary.

The Stelara biosimilar will be commercialized by Sandoz, and is expected to launch by February 2025 for multiple indications, including for the treatment of adult patients with active psoriatic arthritis.

The deal provides the CDMO with ownership of the Lexington facility, allowing for late-phase and commercial gene therapy development and manufacturing of a branded severe Hemophilia B product.

A cross-sectional study evaluates the difference in clinical outcomes and demographics between pediatric RSV patients during these multiple timeframes.

The CRDMO will contribute cell discovery services that will benefit clinical development of novel technologies.

Following the evaluation, the company will decide whether it wants to move forward with the IDMO’s automated, end-to-end, cell therapy manufacturing platform.

The company’s latest investment—featuring new cGMP suites at its Devens, MA plant—is valued at $30 million.

The North Carolina project adds 1.4 million square feet of dedicated production space for aseptic manufacturing and finished production processes.

A cross-sectional audit study determines how racial and ethnic disparities—among English, Mandarin, and Spanish-speaking patients—can impact access.

The deal offers member pharmacies two pricing options, which will take effect Aug. 1.

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

The agreement will look to further develop cell and gene therapies for the treatment of hematological cancers.

A retrospective study investigates whether use of these portals can be defined by clinical and sociodemographic data.

The Hopewell facility—which will serve as the CDMO’s North American hub—is expected to help accelerate the cell and gene therapy delivery process.

The company acquires Alimera Sciences for $381 million upfront, while establishing its interest in ophthalmology.

A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.

The partnership will offer an end-to-end manufacturing solution for biopharma companies.

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

A cross-sectional study explores the broader issue of whether racial segregation in local acute care hospitals exists, while focusing on the demographic of older Black patients enrolled in Medicare.